# US 2026/0091087 A1 · Methods of using and compositions including an incretin analog

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091087 A1
- Document ID: US20260091087A1
- Status: Published application
- Kind: A1
- Application number: 19/393,199
- Filed: 2025-11-18
- Published: 2026-04-02
- Earliest claimed: 2021-06-23
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Tamer COSKUN; Zvonko MILICEVIC; Shweta URVA
- Web page: https://patentgrep.com/patent/US20260091087A1

## CPC

- A61K 38/26: Glucagons
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

## Claims

### Claim at position 1

-94. (canceled)

### Claim 95

A method of treating a condition, disease or disorder in an individual having a body mass index (BMI) of ≥27 kg/m2, the method comprising:
administering to the individual a first once weekly dose of a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist comprising a structure of SEQ ID NO:1, wherein the first once weekly dose is about 2.0 mg and is administered for at least 1 week; and
increasing the first once weekly dose by increments of about 1.0 mg to about 4.0 mg to a once weekly dose of ≤12.0 mg, wherein each increased once weekly dose is administered for at least 1 week; and
wherein the condition, disease or disorder is obstructive sleep apnea (OSA), osteoarthritis (OA), chronic kidney disease (CKD) and/or cardiovascular (CV) disease.

### Claim 96 (depends on 95)

The method of claim 95, wherein the first once weekly dose and each increased once weekly dose are administered for at least about four weeks.

### Claim 97 (depends on 96)

The method of claim 96, wherein the increased once weekly doses are selected from 4.0, 6.0, 9.0, or 12.0 mg.

### Claim 98 (depends on 97)

The method of claim 97, wherein a first increased once weekly dose is 4.0 mg.

### Claim 99 (depends on 98)

The method of claim 98, wherein a second increased once weekly dose is 6.0 mg.

### Claim 100 (depends on 99)

The method of claim 99, wherein a third increased once weekly dose is 9.0 mg.

### Claim 101 (depends on 100)

The method of claim 100, wherein a fourth increased once weekly dose is 12.0 mg.

### Claim 102 (depends on 95)

The method of claim 95, wherein the individual initially has a body mass index (BMI)≥30 kg/m2.

### Claim 103 (depends on 95)

The method of claim 95, wherein the condition, disease or disorder is obstructive sleep apnea (OSA).

### Claim 104 (depends on 95)

The method of claim 95, wherein the condition, disease or disorder is osteoarthritis (OA).

### Claim 105 (depends on 95)

The method of claim 95, wherein the condition, disease or disorder is chronic kidney disease (CKD).

### Claim 106 (depends on 95)

The method of claim 95, wherein the condition, disease or disorder is cardiovascular (CV) disease.

### Claim 107

A method of treating a condition, disease or disorder in an individual having a body mass index (BMI) of ≥27 kg/m2, the method comprising the steps of:
(a) administering to the individual about 2.0 mg of a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist comprising a structure of SEQ ID NO:1 for at least 1 week;
(b) administering to the individual about 4.0 mg of the GGG tri-receptor agonist for at least 1 week; and
(c) administering to the individual about 6.0 mg of the GGG tri-receptor agonist weekly for at least 1 week;
wherein the condition, disease or disorder is obstructive sleep apnea (OSA), osteoarthritis (OA), chronic kidney disease (CKD) and/or cardiovascular (CV) disease.

### Claim 108 (depends on 107)

The method of claim 107, further comprising the step of: (d) administering to the individual about 9.0 mg of the GGG tri-receptor agonist weekly for at least 1 week.

### Claim 109 (depends on 108)

The method of claim 108, further comprising the step of: (e) administering to the individual about 12.0 mg of the GGG tri-receptor agonist weekly for at least 1 week.

### Claim 110 (depends on 109)

The method of claim 109, wherein the individual initially has a body mass index (BMI)≥30 kg/m2.

### Claim 111 (depends on 110)

The method of claim 110, wherein each of steps (a)-(e) comprises administering the GGG tri-receptor agonist for at least 4 weeks.

### Claim 112 (depends on 107)

The method of claim 107, wherein the condition, disease or disorder is obstructive sleep apnea (OSA).

### Claim 113 (depends on 107)

The method of claim 107, wherein the condition, disease or disorder is osteoarthritis (OA).

### Claim 114 (depends on 107)

The method of claim 107, wherein the condition, disease or disorder is chronic kidney disease (CKD).

### Claim 115 (depends on 107)

The method of claim 107, wherein the condition, disease or disorder is cardiovascular (CV) disease.
